Talk Bio

Novo Nordisk continues to expand its Wegovy franchise in the obesity market, with the oral version of Wegovy and higher‑dose injection both reinforcing its positioning despite an overall sales slowdown forecast for 2026. Key developments include FDA approval of Wegovy HD (7.2 mg) and a rapidly growing partition of new prescriptions in the branded obesity market, where Wegovy now leads in new‑to‑brand share by about 65%. The oral Wegovy pill has launched explosively in the U.S., with tens of thousands of weekly prescriptions and over hundreds of thousands of total prescriptions within its first months, and Novo has begun its first international rollout outside the U.S., starting with the UAE. Despite facing stiffer competition from Eli Lilly and a projected 5–13% revenue decline in 2026, Novo’s obesity segment remains central to its strategy, with Wegovy contributing to sustained growth in new patient prescriptions and global GLP‑1 volumes. Sources: Novo Nordisk faces defining...